Abstract Millions of individuals with active TB do not receive recommended treatments, and instead may use botanicals, or use botanicals concurrently with established treatments. Many botanicals protect against oxidative stress, but this can interfere with redox-dependent activation of isoniazid and other prodrugs used for prophylaxis and treatment of TB, as suggested by results of a recent clinical trial of the South African botanical Sutherlandia frutescens (L.) R. Br. (Sutherlandia). Here we provide a brief summary of Sutherlandia's effects upon rodent microglia and neurons relevant to tuberculosis of the central nervous system (CNS-TB). We have observed that ethanolic extracts of Sutherlandia suppress production of reactive oxygen species (ROS) in rat primary cortical neurons stimulated by NMDA and also suppress LPS-and interferon c (IFNc)-induced ROS and nitric oxide (NO) production by microglial cells. Sutherlandia consumption mitigates microglial activation in the hippocampus and striatum of ischemic brains of mice. RNAseq analysis indicates that Sutherlandia suppresses gene expression of oxidative stress, inflammatory signaling and toll-like receptor pathways that can reduce the host's immune response to infection and reactivation of latent Mycobacterium tuberculosis. As a precautionary measure, we recommend that individuals receiving isoniazid for pulmonary or cerebral TB, be advised not to concurrently use botanicals or dietary supplements having antioxidant activity.
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In 2014, approximately 9.6 million people had active TB, which killed 1.5 million people and ranked alongside HIV as a global leading cause of death by infectious agents. Current first-line treatment regimens for TB rely upon isonicotinic acid hydrazide (isoniazid), which can be accompanied by hepato-and neurotoxicities that negatively impact patient adherence and, ultimately, outcomes. Poor adherence to recommended treatments or use of inappropriate treatments may lead to multiple and extreme drugresistant (MDR/XDR) TB, whose prevalence is increasing (WHO 2015a, b) . Approximately a third of those individuals with active TB do not receive recommended treatments and, instead, may use botanicals, and many more may use botanicals concurrently with established treatments to help address side effects and to improve health. This is especially true of individuals who are resourcelimited and/or have strong attachments for traditional practices (WHO 2013).
While there are claims that some botanicals may interfere with TB infection/activation or accentuate proven treatments, a recent placebo-controlled randomized clinical trial (RCT) (Wilson et al. 2015) of Sutherlandia, a botanical widely used in southern Africa for treatment of symptoms of HIV and TB (van Wyk and Albrecht 2008; Davids et al. 2014; Sutherlandia.org 2016) , has provided unsettling evidence for interference with isoniazid preventive therapy (IPT), a first-line regimen used worldwide for prevention and treatment of TB (WHO 2015a, b) . In this RCT, the mean and total burden of infection (BoI; defined as infection-related events in each participant) increased in the Sutherlandia (active) arm, where two cases of active pulmonary TB occurred in subjects, despite their receiving IPT (Wilson et al. 2015) . Additional research is critically needed to determine whether Sutherlandia and other botanicals interfere with isoniazid activation in treatment of pulmonary TB and of central nervous system (CNS) TB. Also, other drugs used for treatment of TB (ethionamide, bicyclic nitroimidazoles such as PA-824) require metabolic activation (Baulard et al. 2000; Singh et al. 2008 ) and could be susceptible to interference by botanicals, as might be other infections treated with drugs susceptible to oxidants.
Isoniazid is peroxidatively activated by the Mycobacterium tuberculosis KatG catalase-peroxidase so as to form adducts with host-derived NAD ? and NADP ? that, together with other reactants, inhibit mycolic acid biosynthesis and other pathways essential for bacterial growth (Timmins and Deretic 2006; Vilcheze and Jacobs 2007) . Isoniazid activation also generates nitric oxide (NO) (Timmins et al. 2004a, b) which, together with NO generated by cellular metabolism, has been strongly implicated in latency and killing of M. tuberculosis (Singh et al. 2008; Yang et al. 2009; Kumar et al. 2011; Voskuil et al. 2011; Mishra et al. 2013) .
ROS and reactive nitrogen species (RNS) are important for the host immune and inflammatory responses. Chronic inflammatory responses mediated by activated microglial cells in the CNS have important roles in the pathogenesis of numerous neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease (Rogers et al. 2007; Qian and Flood 2008; Calabrese et al. 2009; Tsang and Chung 2009; Streit 2010) . Various inflammatory mediators and cytotoxic molecules, such as IL-1a, IL-6, TNF-a, ROS and RNS released by activated microglial cells in response to infection, injury, or endotoxins, may trigger neuronal damage and cell death (Block et al. 2007; Pacher et al. 2007; Yang et al. 2007; Olin et al. 2008; Rock et al. 2008; Brown and Neher 2010; Graeber and Streit 2010; Saenz et al. 2013; Isabel and Rogelio 2014; Francisco et al. 2015) .
Sutherlandia, like many botanicals, contains significant antioxidant and free radical scavenging activities that protect cells against oxidative stress by scavenging ROS and RNS and by preserving intracellular reduced glutathione (GSH/GSSG) ratios (Fernandes et al. 2004; Katerere and Eloff 2005; Tobwala et al. 2014) . Additionally, botanicals modulate cellular production of ROS and RNS, and as detailed in this issue of NeuroMolecular Medicine and elsewhere, these properties are generally viewed as being neuroprotective. However, the concern that botanicals might interfere with current treatment regimens of TB that utilize isoniazid and other prodrugs requiring activation by ROS and RNS has not previously been considered. Here we provide a brief summary of relevant recent and ongoing studies focusing upon Sutherlandia's effects upon aspects of rodent microglia and neurons relevant to CNS infection by M. tuberculosis.
Hematogenous dissemination of M. tuberculosis from primary pulmonary infection and the formation of small foci in the CNS are clinically significant, especially in high TB prevalence countries where CNS-TB is one of the top ten causes of death in children (Rock et al. 2008; Thwaites and Schoeman 2009; Chin and Mateen 2013) . In some individuals, foci rupture and release bacteria into the subarachnoid space causing meningitis; in other individuals, foci enlarge to form tuberculomas without meningitis. The timing and frequency of these events in relation to primary pulmonary infection is dependent upon age, immune status and other factors (Rock et al. 2008; Thwaites and Schoeman 2009; Chin and Mateen 2013) . With cerebral TB, microglia, neurons and oligodendrocytes are targeted by the invading bacilli (Randall, Hsu et al. 2015) , and consequent tissue damage and neurodegeneration are caused by infection and excessive cellular-mediated immune response and inflammation (Rock et al. 2008; Saenz et al. 2013; Isabel and Rogelio 2014) .
We have observed that ethanolic extracts of Sutherlandia suppress production of ROS in rat primary cortical neurons stimulated by NMDA, and also, these extracts suppress LPS-and interferon c (IFNc)-induced ROS and NO production by microglial cells. Its action on microglial cells appears to be mediated through inhibition of p-ERK1/ 2 and NF-kB signaling pathways (Jiang et al. 2014) . Also, Sutherlandia consumption mitigates microglial activation in the hippocampus and striatum of ischemic brains of mice and is accompanied by reduced expression of p47phox, a subunit of NADPH oxidase, and p-ERK1/2 . It is possible that these anti-oxidative and anti-inflammatory effects of Sutherlandia, while generally protective of uninfected cells, reduce the host's immune response to infection by M. tuberculosis and promote reactivation of latent M. tuberculosis. Additionally, recent studies by others with a human cell culture model of the blood brain barrier (BBB) suggests that Sutherlandia extracts exacerbate HIV-associated neuroinflammation and promote monocyte migration across the BBB (Africa and Smith 2015) ; this might increase the dissemination of bacilli into the CNS of HIV-infected individuals who are especially vulnerable to TB.
Recent analyses of gene expression of non-CNS cells infected by M. tuberculosis or stimulated by elicitors provide important insights about genes and pathways important for M. tuberculosis replication and latency. Furthermore, experimentally verified intraspecies and interspecies protein interactions have been used to predict human-M. tuberculosis interactions that were further filtered using genes known to be differentially expressed during infection; host proteins and pathways involved in apoptosis and NO production were found to be especially highly represented (Rapanoel et al. 2013) . To begin to relate these seminal findings to effects of Sutherlandia upon gene expression of infected cells, we have analyzed patterns of gene expression of rodent microglial cells alone, or stimulated with LPS ? IFNc, together with ethanolic extracts of Sutherlandia (Sun et al. unpublished) . Total RNA was isolated, purified and used to generate sequencing libraries, and sequenced and analyzed by RNAseq analyses as described by (Lu et al. 2015) . Detailed assessment of these experiments will be reported separately, but using Ingenuity Ò Pathway Analysis software, we compared experimental groups through canonical signaling pathways and through genes grouped to common diseases and functions. One pathway of particular interest was the ''Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses,'' which exhibited significant activation by LPS ? IFNc treatment, but this activation was suppressed by concurrent exposure to Sutherlandia extracts. More generally, Sutherlandia extract inhibited gene expression of activated leukocytes and lymphocytes, regardless of stimulus. We observed significant reduction in expression of NFkB and iNOS gene subunits and genes regulated by pERK and pERK1/2, and genes for certain inflammatory cytokines and proteins related to toll-like receptors, such as interferon b1 (IFNB1), chemokine ligand 5 (CCL5), interleukin 6, 15 and 27) (IL6, IL15, IL27), dual specificity phosphatase 1 (DUSP1), inducible NO synthase (NOS2), suppressor of cytokine signaling (SOCS1), CD69 and CD80 antigens (CD69, CD80), and prostaglandin-endoperoxide synthase 2 (PTGS2). Several of these results concur with the observations of protein expression in microglia and neurons described in the previous section, and others remain to be confirmed by analysis of protein expression.
Together, these observations indicate that Sutherlandia, in addition to quenching ROS and RNS, modulate gene expression of a variety of immune function genes that may predispose to M. tuberculosis infection, reactivation from latency and the consequent inflammatory responses.
Clearly, these preliminary findings require confirmation and extension in M. tuberculosis-infected cells and animals, so as to fully understand the potential for Sutherlandia and other botanicals to interfere with treatment of TB in humans by isoniazid and other prodrugs requiring metabolic activation, and whose therapeutic activities include production of RNS. However, as a precautionary measure, we recommend that individuals receiving IPT and other drugs requiring metabolic activation for pulmonary TB and isoniazid treatment for cerebral TB, be advised not to concurrently use botanicals or dietary supplements having antioxidant activity. Further research of infections of the nervous system (John et al. 2015) should include studies of the use of botanicals and dietary supplements by the public.
